PL02.12 Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi
J.W. Goldman, A. Passaro, J. Laskin, D. Rodrigues-Abreu, Antonio Calles, L. Bazhenova, Giuseppe Lo Russo, N. Leighl, F. Cappuzzo, N. Girard, S. Popat, Weizhen Fang, Ying Luo, Rong Yang, Wenyu Li, Junmin Li, Lori Styles, Bruce Thompson, Lin Zhang, X. Le
Topics & Concepts
MedicineInternal medicineOncologyPlaceboPhases of clinical researchLung cancerChemotherapyBevacizumabnon-small cell lung cancer (NSCLC)Vascular endothelial growth factorDiseaseAntibody therapyTargeted therapyPerformance statusClinical trialClinical endpointCancerSafety profileCirculating tumor cellGastroenterologyLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies